The Lancet Infectious Diseases· Bakary Fofana, Rella Zoleko-Manego, Ghyslain Mombo-Ngoma, Andre Toure Offianan, Mulenge Kilowele, Amadou Hamidou Togo, Jean Moïse T Kaboré, Souleymane Dama, Oumar Bila Traore, Peter G Kremsner, Rakiswendé Serge Yerbanga, Mohamed Boly, Kanga Didier N’guetta, Waota Guy Matthieu Toure, Franck Sango, Martel Ngoy Musodi, Anne Claire Marrast, Stephan Duparc, Myriam El-Gaaloul, Cornelis Winnips, Celine Risterucci, Saneesh Kumar, Guoqin Su, Gen Zhu, Jared Thornton, Ramachandra Sangana, Jayant Sancheti, Hira Choudhury, Zhiyan Qian, Alassane Dicko, Issaka Sagara, Jean Bosco Ouedraogo, Sodiomon Bienvenu Sirima, Martin Peter Grobusch, Abdoulaye Djimde·· 19 小时前AI 评分51
KALUMI II 期试验：Ganaplacide 联合苯芴醇固体分散制剂治疗儿童疟疾达到非劣效
[Articles] Ganaplacide plus lumefantrine solid dispersion formulation for children with uncomplicated Plasmodium falciparum malaria (KALUMI): an open-label, multicentre, randomised, controlled, adaptive, phase 2, non-inferiority trial
AI 导读
KALUMI 试验显示，Ganaplacide 联合苯芴醇（lumefantrine）固体分散制剂治疗儿童非复杂性恶性疟疾，疗效非劣于蒿甲醚联合苯芴醇。该研究为开放标签、多中心、随机对照、自适应 II 期非劣效试验，方案为 Ganaplacide 400 mg 加苯芴醇固体分散制剂 480 mg，每日一次、连续 3 天，随清淡餐食服用。
来源：The Lancet Infectious Diseases · thelancet.com